• An Early-Stage THx, Dx & Device Focus:

    Welcome to the site formerly known as [Colorado] Life Science Deal Flow. This new version looks at the biopharma world primarily from an early-stage financing perspective. Be certain to visit our companion site, a FREE Venture Capital dBase, OnBioVC.com, and subscribe by email or RSS.
  • SEARCH the Life Science Deal Flow ARCHIVE

  • business strategy life science

ARCA Discovery has changed their name to ARCA Biopharma. The modification in moniker more appropriately correlates with the enterprises graduation from a discovery to now a commercialization focus as demonstrated by a planned 2008 NDA filing with the FDA. A beautiful new website and logo has been rolled out as well. Take a look (here). [...]

…To a deluxe apartment, wait, make that a deluxe new office in the sky. ARCA Discovery is currently headquartered in LoDo, the labs however at last check remain at the Colorado Science + Technology Park @ Fitzsimons and, I would venture to guess shall remain there as plans are finalized to make the move north [...]

The winner of the CLSDF Reader’s Choice Company of the Year, 2007 goes to… GlobeImmune, Inc., who took home a commanding 43% of the vote. ARCA Discovery and ValveXchange came in tied for second place. Congratulations to President and CEO Tim Rodell, MD and the other 60+ folks in Louisville who are doing outstanding work.
For [...]

If memory serves me correctly I have waxed on in the past about my affinity for Genetic Engineering News and often highlighted the journal when a Colorado company ended up in print there. Well the love story continues with the 15 November issue where Carol Potera composed a three-page treatise on the Colorado Science + [...]

It is exciting to see how the Colorado community is heating up around biomarkers and diagnostics. What is even hotter to me is when one of these molecular diagnostics forge an intimate relationship with and become a companion to enabling a genetically targeted therapeutic.
Well, we here in Colorado are lucky to have one such company [...]

ARCA Discovery, Inc. closed an $18M Series B led by Skyline Ventures and additional new investor InterWest Partners, previous investors Atlas Ventures, Boulder Ventures and the Peierls Foundation also participated in the round.
ARCA is aiming for an NDA submission in 2007 for Bucindolol, a next-generation beta-blocker and vasodilator for heart failure, and plans to seek [...]

LIVE Thursday 8:00 – 9:00am MST
Dr. Bristow was the principal founder, chief science & medical officer and director of Myogen. In November of 2006 Gilead acquired Myogen for $52.50/share or a whopping $2.5 billion! Dr. Bristow is Professor of Medicine and the former Head of Cardiology, University of Colorado Health Sciences Center, the Co-Director of [...]

ARCA Discovery, Inc., (Denver,CO) a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, announced that Richard B. Brewer has been appointed President and CEO.
Prior to ARCA Discovery Mr. Brewer was managing partner at Crest Asset Management, previously, Mr. Brewer was president and CEO of Scios, Inc. (NYSE: JNJ), served as chief [...]

ARCA Discovery, Inc., a company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, today announced the completion of a $15 million venture capital financing. The financing was led by Atlas Venture. Boulder Ventures, which provided the original seed financing for ARCA, and Pequot Capital Management also participated in the financing.
This round of financing [...]

  

to top of page...


 
  • The Latest LSDF Activity

    July 2010
    M T W T F S S
    « May    
     1234
    567891011
    12131415161718
    19202122232425
    262728293031  
  • Search the LSDF Archive

  • Your Advert Can Go Here!

    Find out how, email: arubenstein@rnaventures.com